Future research should aim to explore the relationship between dose – bioavailability- and efficacy and further define the pleiotrophic mechanisms of actions in humans.
Table 1 Pharmacokinetic parameters of KH176 and KH176m in mice and rats, derived from a single dose pharmacokinetics and bioavailability study.
The final structural model, including body weight as an allometric function on clearance and volume parameters as well as between-subject variability on all parameters and between-dose occasion variability on relative bioavailability and mean absorption time, was also used to investigate the impact of concomitant fat intake on absorption parameters with a full covariate approach (23).
Dosing vehicles and bioavailability-enabling formulations that can be used for discovery and preclinical studies are described.
Serum conbercept concentrations after IVT dosing were low and bioavailability was approximately 44%.
Implementation of a fixed relative bioavailability of 100% for the population but allowing for between-subject variability and between-dose occasion variability (i.e., modeled as within-subject variability between doses) in the same parameter was also evaluated.
Implementation of a fixed relative bioavailability of 100% for the population but allowing for between-subject variability and between-dose occasion variability in the same parameter improved the model fit significantly (ΔOFVs of −46.1 and −160, respectively, when implemented sequentially).
The pharmacokinetics of degarelix after subcutaneous injection were also found to be dose- and concentration-dependent, and bioavailability was estimated at 30%to40%0% following both subcutaneous and intramuscular administration.
Food delayed Tmax (from 1 to 4 hrs post dose), and famotidine coadministration reduced bioavailability (Cmax ~26%, AUC ~42%).
The F, D, and Vd represent the bioavailability, dose, and volume of distribution, respectively.
